Hormonal
Second-generation anti-obesity medications (semaglutide 2.4 mg and tirzepatide) induce significantly greater weight loss (15-21%) compared to traditional lifestyle modification (5-10%) by pharmacologically enhancing satiation and reducing hunger, thereby decreasing the reliance on cognitive behavioral strategies for calorie restriction.
If you have obesity, second-generation medications like semaglutide or tirzepatide are significantly more effective than lifestyle changes alone, producing 15-21% weight loss compared to 5-10%. They work by reducing hunger and increasing fullness, which reduces the mental effort needed to restrict calories. While they require weekly injections and gradual dose titration to manage side effects, they represent a major advancement in obesity treatment.
Semaglutide reliably reduces baseline body weight by approximately 15% at 68 weeks, in contrast to 5–10% for lifestyle modification. Tirzepatide induces mean losses as great as 20.9%. Both medications reduce energy intake by markedly enhancing satiation and decreasing hunger, and they appear to lessen the need for traditional cognitive and behavioral strategies (e.g., monitoring food intake) to achieve calorie restriction.
Why this rating
Based on multiple phase 3 randomized controlled trials (STEP 1-8, SURMOUNT-1-3) with large sample sizes and long durations.
Source
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
Thomas A. Wadden et al. · Current Obesity Reports · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →